|Day Low/High||69.30 / 75.55|
|52 Wk Low/High||20.10 / 300.00|
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.
Apparently, this game is all about growth right now. It certainly is not about margins.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Let's check out the charts and indicators for this so-called pot play.
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
This quarter is a heavy test for Tilray because of the stock's lofty valuation.
Assessing Aurora and its peers, strictly on the numbers.
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
The price of ACB is moving up today and a fresh look at the charts and indicators seems like a good idea.
In its first report on cannabis companies, Melius says prices are high.
In an industry where Canadian companies have been grabbing the headlines, New York-based Acreage Holdings has methodically built itself into the largest American cannabis firm.
Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.
China trade discussions will continue to be a key driver in Wednesday's market action.
There are some big shifts Wednesday in names that have recently been the hottest.
Let's check out the charts of four big names in the space.
CBD could make coffee an around the clock craze.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
"One last thing." -- Lt. Columbo I have recently been focused on Canopy Growth Corp. CGC as an interesting speculation in 2019 (I have been adding over the last few days). In fact, I commented today on the stock. After the close, Tilray was upgraded...
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
Establishing who the stragglers are and what impact they might have in the future is the key at this point.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Perhaps no company has bought into the Canadian cannabis craze more than Constellation Brands.